Navigation Links
President Obama selects Rutgers cell biologist Nihal Altan-Bonnet to receive prestigious award
Date:7/24/2012

Fewer than 100 researchers nationwide are chosen each year to receive the Presidential Early Career Award for Scientists and Engineers (PECASE), and this year Dr. Nihal Altan-Bonnet is one of the 96 to receive this honor.

"Dr. Nihal Altan-Bonnet is a superb cell biologist in the Department of Biological Sciences at Rutgers University, Newark, pursuing in her research an understanding of viral replication in infected cells," noted Interim Chancellor Philip Yeagle. "That her outstanding research has now attracted one of the highest honors a young scientist in this country can receive gives us here at Rutgers great joy and pride. She is the second member of our faculty to have received this rare honor in the past two years, which speaks to the extraordinary quality of our faculty on the Newark campus of Rutgers University."

Altan-Bonnet, a member of the Rutgers-Newark faculty since 2006, is one of two New Jersey researchers, one from Rutgers and one from Princeton, receiving this year's PECASE award. She has been cited for "research identifying a common lipid blueprint for viral replication and potential panviral therapeutics." She will join the other honorees for a White House ceremony with President Barack Obama this fall.

Nihal Altan-Bonnet, a resident of New York City, received her bachelor of science degree from Hunter College and her doctoral degree in cell biology from The Rockefeller University, both in New York City. Her research has been widely published in academic journals, most recently in Cell, Trends in Biochemical Sciences, Journal of Virology, Proceedings of the National Academy of Sciences, Journal of Cell Science, Nature Cell Biology and Molecular Biology of the Cell.

"The viral repertoire on our planet is dominated by RNA (ribonucleic acid) viruses," explains Altan-Bonnet. "Many of them are pathogenic and cause human diseases with major health and socioeconomic consequences such as poliomyelitis, influenza, hepatitis, SARS, AIDS, Ebola and the common cold." (An RNA virus is a virus that has RNA, rather than DNA, as its genetic material.) "Individuals can often be infected with multiple different viruses at a given time. Hence, development of panviral therapeutics is an urgent need in combating these types of multiple viral infections."

Many of the pathogenic RNA viruses use their host cells' intracellular membranes as a platform on which to replicate themselves. With grants from the National Institutes of Health, Altan-Bonnet and her "Host-Pathogen Dynamics" lab group have been studying the molecular nature of these platforms. They have found that viruses, before they start replication, remodel the membranes into their "perfect replication" platform.

Altan-Bonnet has discovered that there is a common membrane blueprint for the perfect replication platform, shared by multiple different viruses including ones that cause the common cold, poliomyelitis and hepatitis C.

Altan-Bonnet and her colleagues have identified critical lipid molecules present within these platforms that viruses rely upon for replication. Having identified these molecules and where they are derived from in the host cell, Altan-Bonnet is now working with industry partners to design and test therapeutics targeting their virus production, that will address panviral effectiveness.

More information on Altan-Bonnet's research is available at http://runewarkbiology.rutgers.edu/department/FacultyProfiles/altan-bonn...

About PECASE

PECASE awardees are selected for their pursuit of innovative research at the frontiers of science and technology, and their commitment to community service as demonstrated through scientific leadership, public education, or community outreach. Winning scientists and engineers receive research grants for up to five years to further their studies in support of critical government missions.

In a statement announcing the awards, President Obama said, "Discoveries in science and technology not only strengthen our economy, they inspire us as a people. The impressive accomplishment s of today's awardees so early in their careers promise even greater advances in the years ahead."

Ten federal departments and agencies join together annually to nominate scientists and engineers whose early accomplishments show the greatest promise for assuring America's preeminence in science and engineering and contributing to the awarding agencies' missions. Altan-Bonnet was nominated by the National Institutes of Health, Department of Health and Human Services.

The awards, established by President Clinton in 1996, are coordinated by the Office of Science and Technology Policy within the Executive Office of the President.


'/>"/>
Contact: Helen Paxton
paxton@andromeda.rutgers.edu
973-353-5262
Rutgers University
Source:Eurekalert  

Related medicine news :

1. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
2. Hutchinson Center president elected to American Academy of Art and Sciences
3. Presidential Recognition Awards presented during the 2012 AIUM Annual Convention
4. First recipients of AcademyHealths Presidential Scholarship announced
5. UT MD Anderson President Ronald DePinho elected to National Academy of Sciences
6. Dr. Arthur Slutsky, vice-president of research at St. Michaels, receives lifetime award
7. Presidential candidates should address childhood obesity and bullying, poll says
8. President Obama names SF State math professor a top young scientist
9. Chinese Drywall Complaint Center Now Demands Leadership From Obama & EPA, For Homeowners In Florida And In The US Southeast Stuck In Toxic Chinese Drywall Hell-Forward?
10. The Gerontological Society of America Selects 2012 Fellows
11. Rutgers team discovers novel approach to stimulate immune cells
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
President Obama selects Rutgers cell biologist Nihal Altan-Bonnet to receive prestigious award
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical Therapy ... the preferred physical therapy provider for Derby City CrossFit, effective immediately. , In ... as quickly and effectively as possible, ProRehab’s sports physical therapists will work with ...
(Date:4/25/2017)... ... April 25, 2017 , ... A ... student test score performance for the 2015-16 school year across Wisconsin’s public schools, ... Though it highlights important patterns in student test score performance, the report’s limited ...
(Date:4/25/2017)... ... April 25, 2017 , ... As ... contracted partners to help with process innovation in drug formulation and manufacturing. ... along with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
(Date:4/25/2017)... ... ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine care to ... preventative care with all my patients to alleviate possible future issues. I am pleased to ... my office and my trained staff will assist you in any way possible.” , Dr. ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Conference at the InterContinental Hotel in Boston, ... Biomet will present at 11:20 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... -- Research and Markets has announced the addition of ... Expanding Injectables Market and Increasing Usage of Complex Biologics during the ... ... from USD 20 Billion in 2015 to around USD 26 Billion ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
Breaking Medicine Technology: